Tiziana Life Sciences Expands Phase 2 MS Trial with New Site

An update from Tiziana Life Sciences ( (TLSA) ) is now available.

On June 13, 2025, Tiziana Life Sciences announced the commencement of patient dosing at Weill Cornell Medicine Multiple Sclerosis Center in New York City for their Phase 2 clinical trial of intranasal foralumab, targeting non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This expansion marks the fifth site in their ongoing trial, joining other prestigious institutions like Yale and Johns Hopkins. The trial aims to evaluate the safety and efficacy of foralumab, positioning Tiziana at the forefront of innovative therapies for MS and other neurodegenerative diseases. The trial’s design includes a six-month open-label extension phase to assess long-term safety and benefits, highlighting Tiziana’s commitment to addressing unmet medical needs in MS treatment.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody, currently in clinical development for treating neuroinflammatory and neurodegenerative diseases, offering potential improvements in efficacy, safety, and tolerability compared to traditional intravenous delivery methods.

Average Trading Volume: 380,970

Technical Sentiment Signal: Buy

Current Market Cap: $162.7M

See more insights into TLSA stock on TipRanks’ Stock Analysis page.